PURPOSE PRESIDER/PRESENTER(s)

8:00 Dr. Nancy Bennett (ACIP Chair)

Dr. Amanda Cohn (ACIP Executive Secretary; CDC)

8:30 Hepatitis Vaccines 

Introduction

Review of GRADE (HEPLISAV-B)

Considerations and proposed recommendations

Public comment

Vote

Hepatitis A post-exposure prophylaxis GRADE

Considerations and proposed recommendations 

Public comment

Vote

Dr. Jose Romero (ACIP, WG Chair)

Dr. Aaron Harris (CDC/NCHHSTP)

Dr. Sarah Schillie (CDC/NCHHSTP)

Dr. Sarah Schillie (CDC/NCHHSTP)

Dr. Noele Nelson (CDC/NCHHSTP)

Dr. Noele Nelson (CDC/NCHHSTP)

Dr. Noele Nelson (CDC/NCHHSTP)

10:15

10:30 Influenza Vaccines

Introduction Dr. Chip Walter (ACIP, WG Chair)

Dr. Leonard Friedland (GSK)

Ms. Lynnette Brammer (CDC/NCIRD)

Dr. Brendan Flannery (CDC/NCIRD)

Dr. Raburn Mallory (MedImmune/AstraZeneca)

Dr. Lisa Grohskopf (CDC/NCIRD), Dr. Jill 

Ferdinands (CDC/NCIRD)

Dr. Lisa Grohskopf (CDC/NCIRD)

Vote Dr. Lisa Grohskopf (CDC/NCIRD)

VFC Vote VFC Vote Dr. Jeanne Santoli

12:45

1:45

Introduction Dr. Grace Lee (ACIP, WG Chair)

Dr. Wendy Carr (CDC/NCIRD)

Vote Vote Dr. Wendy Carr (CDC/NCIRD)

2:30

Dr. David Stephens (ACIP, WG Chair)

Dr. William Bower (CDC/NCEZID)

Dr. William Bower (CDC/NCEZID)

Dr. William Bower (CDC/NCEZID)

3:45

4:00

Introduction Dr. Peter Szilagyi (ACIP, WG Chair)

Dr. Jorge Arana (CDC/NCEZID)

Dr. Jim Donahue (Marshfield Clinic)

Dr. Lauri Markowitz (CDC/NCIRD)

Dr. Elizabeth Van Dyne, (CDC/NCCDPHP)

Dr. Anil Chaturvedi (NIH/NCI)

5:30

5:45 Adjourn

Break

9-valent HPV vaccine rapid cycle analysis, Vaccine Safety

Trends in HPV-associated cancers in the United States

Epidemiology of HPV infection in males

Public Comment

Harmonization of upper age for male and female vaccination

recommendations

Information 

& Discussion

Introduction

Update on IM route of administration of vaccine

Dose-sparing strategies when demand for vaccine excess 

Duration of antimicrobial component of PEP when used in 

combination with anthrax vaccine

Surveillance update 

VE update

Results of a randomized trial of a new H1N1 LAIV strain in US 

children

Considerations and proposed recommendations

Public comment

9-valent HPV vaccine safety data - VAERS update

Human Papillomavirus (HPV) Vaccines 

Public comment

Review of LAIV for 2 through 17 year olds

Lunch

Anthrax

Vote

Wednesday, February 21

Welcome & Introductions

Centers for Disease Control and Prevention

1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium

AGENDA ITEM

Atlanta, Georgia 30329 

February 21-22, 2018

Information 

& Discussion

Vote

Information 

& Discussion

Vote

Break

Evidence to Recommendations Framework Information 

& Discussion

Information 

& Discussion

Information 

& Discussion

Evidence Based Recommendations

Fluarix Quadrivalent: efficacy in children 6-35 months of age

This document has been archived for historical purposes. (4/12/2018)
8:00

Information Dr. Nancy Messonnier (CDC/NCIRD); Ex Officio

Members

9:00

Dr. Grace Lee (ACIP, WG Chair)

Dr. Tamara Pilishvili (CDC/NCIRD)

Dr. Tamara Pilishvili (CDC/NCIRD)

Dr. John M. McLaughlin (Pfizer Vaccines)

Dr. Almea Matanock (CDC/NCIRD)

10:30

Information Dr. Anthony Fiore (CDC/NCEZID)

11:00

11:30

Introduction Dr. David Stephens (ACIP, WG Chair)

Dr. Sarah Meyer (CDC/NCIRD)

12:00

Dr. Chip Walter (ACIP, WG Chair)

Dr. Susan Hills (CDC/NCEZID)

12:15 Information Dr. Jeanne Santoli (CDC/NCIRD)

12:20 Public Comment

12:30 Adjourn

Acronyms

CDC

CMS

DoD

DVA

FDA

GRADE

HRSA

IHS

JE-VC

NCHHSTP

NCIRD

NCEZID

NCI 

NIH

NVPO

PCV13

VFC

WG

Vaccine Supply

Japanese Encephalitis (JE) Vaccine

Pneumococcal

Thursday, February 22

Break

Vaccines and other biologics for prevention and treatment of 

healthcare-associated infections

PCV13 Direct and Indirect Effects among Adults ≥65 Year Old

PCV13 effectiveness against pneumococcal pneumonia among 

U.S. Adults

Estimating Burden of Pneumococcal Pneumonia among Adults 

in the U.S. Progress of the research agenda to inform potential 

policy change

Work Group

National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] 

Vaccines for Children

Health Resources and Services Administration

Indian Health Service

National Vaccine Program Office

National Center for Emerging and Zoonotic Diseases [of CDC/OID]

National Center for Immunization & Respiratory Diseases [of CDC/OID] 

Vero cell culture-derived Japanese encephalitis 

13-valent pneumococcal conjugate vaccine

National Cancer Institute

National Institutes of Health

Grading of Recommendations Assessment, Development and Evaluation

Agency Updates & Unfinished Business

Centers for Medicare and Medicaid Services 

Centers for Disease Control & Prevention

Food and Drug Administration

Department of Veterans Affairs

Department of Defense

Introduction

Introduction

PCV13 Effectiveness: Case Control Study

Information 

& Discussion

Update

CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO

Review of JE and work group plans

Information 

& Discussion

Information 

& Discussion Epidemiology of meningococcal disease among college 

students – United States, 2014-2016

Meningococcal Disease

This document has been archived for historical purposes. (4/12/2018)